News

 

Contact Media Relations

Office telephone: +39 0331 581380
mediarelations@nmsgroup.it

CANCER PATIENTS TO BENEFIT FROM NEW HISTOLOGY INDEPENDENT TREATMENT

25.06.2020 Entrectinib (Rozlytrek, Roche), a revolutionary treatment for a range of cancers, is the second histology independent drug to be recommended by NICE for use on the Cancer Drugs Fund (CDF). As a histology independent treatment, entrectinib targets all solid...

NICE APPROVES NEW RARE LUNG CANCER TREATMENT FROM ROCHE

15.06.2020 By Emma Morriss, Pharmafield The National Institute for Health and Care Excellence (NICE) has approved a new rare lung cancer treatment. NICE has published its decision to grant a positive final appraisal document (FAD) for the use of Roche’s Rozlytrek®▼...

 Our Archive

MEDIA RELEASES & NEWS 2020
MEDIA RELEASES & NEWS 2019
MEDIA RELEASES & NEWS 2018
MEDIA RELEASES & NEWS 2020
MEDIA RELEASES & NEWS 2019
MEDIA RELEASES & NEWS 2018

 

Welcome and Check out our new motion picture!

WATCH OUR VIDEO